Updated March 8, 2026. To give you technically accurate, evidence-based information, content published on the Everlywell blog is reviewed by credentialed professionals with expertise in medical and bioscience fields.
Everlywell works with preferred partners. If you click on links or make a purchase through this page, we may earn a commission.
Semaglutide is part of a relatively new class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications are among the newer options for weight management and have been shown to be effective for some individuals.
Semaglutide is available in both oral and injectable forms. While it was originally developed to treat type 2 diabetes, it has since been approved for the treatment of obesity. If you’re exploring semaglutide treatment, you may be wondering about the difference between pens vs. needles for semaglutide and which option may be right for you.
The Obesity Epidemic
Obesity is a global health concern affecting more than 1 billion people. Rates of obesity worldwide have more than doubled since 1990 among adults and have increased more than fourfold among children and adolescents.[1]
Obesity is associated with a number of health conditions, including:[2]
- High blood pressure
- High cholesterol
- Heart disease
- Type 2 diabetes
- Asthma
- Sleep apnea
- Osteoarthritis and other musculoskeletal disorders
- Gallstones and gallbladder disease
- Anxiety and depression
- Low self-esteem
- Decreased quality of life
- Increased risk of being bullied, especially in children and adolescents
- Certain types of cancer
With so many potential health impacts, many people are exploring medical options to support weight loss. One such option is semaglutide, which is marketed under several brand names including Ozempic® (for type 2 diabetes), Wegovy® (for obesity), and Rybelsus® (an oral version used for type 2 diabetes).
Semaglutide may also be available from some pharmacies as a compounded medication.
Pens vs. Needles
Semaglutide injections are administered subcutaneously, meaning they are injected just under the skin. Wegovy® is typically provided as a pre-filled injection pen. To use the pen, you dial the prescribed dose, press the needle into the skin, and press the button to administer the medication.
Compounded semaglutide is often provided in a vial and administered using a syringe and needle that draws the medication from the vial. Regardless of the delivery method, semaglutide and other GLP-1 medications are only available by prescription.
| Feature | Semaglutide Injection Pen | Semaglutide Syringe and Needle (Vial) |
|---|---|---|
| How it is provided | Pre-filled pen containing a set dose of medication (such as Wegovy®). | Medication is provided in a vial and drawn into a syringe before injection. |
| How it is used | The user dials the prescribed dose, places the needle against the skin, and presses a button to inject the medication. | The user draws the correct dose from the vial using a syringe and then injects it under the skin. |
| Ease of use | Generally easier to use and designed for convenient self-injection. | Requires measuring the dose manually and may involve more preparation. |
| Common availability | Often used with branded medications such as Wegovy®. | More commonly used with compounded semaglutide formulations. |
| Prescription requirement | Both delivery methods require a prescription from a licensed healthcare provider. | |
Cost and Availability
For many people, the choice between different forms of semaglutide comes down to cost and availability. Wegovy® has a retail price of around $1,350 for a four-week supply.[3] Insurance coverage varies widely, and many insurance plans do not cover medications for obesity.[4]
Supply shortages have also affected access to GLP-1 medications. Wegovy® and other semaglutide medications have experienced periods of limited availability, making it difficult for some patients to obtain their prescriptions.[5]
During the height of the shortages, healthcare providers sometimes had to adjust dosing strategies to help patients maintain treatment.[6]
Novo Nordisk, the manufacturer of Wegovy® and Ozempic®, has reported efforts to increase production and improve supply, though demand may still exceed availability in some areas.[7]
Compounded semaglutide may be more readily available in some cases and may be less expensive for certain patients. Some individuals choose this option when branded medications are difficult to obtain or not covered by insurance.[8]
Are Compounded Medications Safe?
Compounding pharmacies are legal and can provide important services by preparing medications in customized forms. For example, they may produce liquid versions of medications for individuals who cannot swallow pills.
Compounding pharmacies may also prepare medications that are currently in short supply, which is one reason semaglutide may be compounded.[9]
However, compounded medications are not approved by the U.S. Food and Drug Administration in the same way as branded medications. There have been concerns related to counterfeit medications and varying quality among compounding pharmacies.[10,11]
As supply shortages improve, there are also ongoing questions about the legality of continuing to compound certain medications.[12] For this reason, it is important to carefully research any pharmacy or provider offering compounded medications.
Navigating Your Weight Loss Journey
Obesity is a chronic medical condition similar to diabetes or high cholesterol. For many people, weight management can be challenging due to a variety of biological, social, and healthcare barriers.
Historically, obesity has been under-treated, and many healthcare providers have received limited training in obesity medicine.[13] Fortunately, medical options for weight management continue to evolve, giving patients more choices than ever before.
Getting Support for Your Weight Loss Journey
If you’re exploring medications such as semaglutide, speaking with a healthcare provider can help you better understand your options. A provider can review your health history, discuss potential risks and benefits, and determine whether treatment may be appropriate for your goals.
Some individuals choose to explore telehealth weight management programs that connect patients with licensed providers who can evaluate eligibility for medications like semaglutide and help create a personalized treatment plan.
References
- Phelps NH, Singleton RK, Zhou B, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet. 2024;403(10431):1027-1050. doi:10.1016/s0140-6736(23)02750-2
- Childhood obesity is a complex health issue. Centers for Disease Control and Prevention. Published July 15, 2022. Medical Citation URL.
- Warren K. How much does Wegovy cost without insurance? GoodRx. Published April 12, 2024. Medical Citation URL.
- Obesity Medicine Association. Does insurance cover weight loss medication? Obesity Medicine Association. Published July 29, 2024. Medical Citation URL.
- Mahase E. GLP-1 shortages will not resolve this year, EMA warns, amid concern over off-label use. BMJ. Published online June 28, 2024:q1448. doi:10.1136/bmj.q1448
- Whitley HP, Trujillo JM, Neumiller JJ. Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clinical Diabetes. 2023;41(3):467-473. doi:10.2337/cd23-0023.
- Supply update. Novo Nordisk. Medical Citation URL
- Suran M. As Ozempic’s popularity soars, here’s what to know about semaglutide and weight loss. JAMA. 2023;329(19):1627. doi:10.1001/jama.2023.2438
- Research C for DEA. Compounding and the FDA: questions and answers. U.S. Food And Drug Administration. Published August 5, 2024. Medical Citation URL
- Spitery A, Elder MJ, Farhat N, Mohammad I, Lobkovich A. Legal, safety, and practical considerations of compounded injectable semaglutide. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. Published online June 29, 2024. doi:10.1002/jac5.1999
- Lowe D. Compounded (And counterfeit) semaglutide. Science | AAAS. Published January 2, 2024. Medical Citation URL
- Wingrove P. Wegovy maker Novo Nordisk sues nine spas, clinics, and pharmacies over copycat drugs. Reuters. Published May 30, 2024. Medical Citation URL.
- Tucker S, Bramante C, Conroy M, et al. The most undertreated chronic disease: Addressing obesity in primary care settings. Current Obesity Reports. 2021;10(3):396-408. doi:10.1007/s13679-021-00444-y
Spotlight on
Featured content
Explore Everlywell
